Clinical Cancer Research · 2023 · 14 citations · 35 references
MedicineOncologyPharmacologyChemotherapyMetastasisMolecular OncologyCancer ImmunotherapyMetastatic Breast CancerMetastatic Disease TreatmentMolecular Tumor ProfilingNext-generation Sequencing In OncologyTargeted TherapyBreast Cancer ChemotherapyBreast Cancer Response AssessmentMetastatic Breast Cancer TreatmentPembrolizumab TherapyPhase Ii Clinical TrialsRna SequencingTranscriptomic BiomarkersTriple-negative Breast Cancer Therapy
PURPOSE: A single arm, phase II trial of carboplatin, nab-paclitaxel, and pembrolizumab (CNP) in metastatic triple-negative breast cancer (mTNBC) was designed to evaluate overall response rate (ORR), progression-free survival (PFS), duration of response (DOR), safety/tolerability, overall survival (OS), and identify pathologic and transcriptomic correlates of response to therapy. PATIENTS AND METHODS: Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor programmed cell death-ligand 1 status. Core tissue biopsies were obtained prior to treatment initiation. ORR was assessed using a binomial distribution. Survival was analyzed via the Kaplan-Meier method. Bulk RNA sequencing was employed for correlative studies. RESULTS: Thirty patients were enrolled. The ORR was 48.0%: 2 (7%) complete responses (CR), 11 (41%) partial responses (PR), and 8 (30%) stable disease (SD). The median DOR for patients with CR or PR was 6.4 months [95% confidence interval (CI), 4-8.5 months]. For patients with CR, DOR was >24 months. Overall median PFS and OS were 5.8 (95% CI, 4.7-8.5 months) and 13.4 months (8.9-17.3 months), respectively. We identified unique transcriptomic landscapes associated with each RECIST category of radiographic treatment response. In CR and durable PR, IGHG1 expression was enriched. IGHG1high tumors were associated with improved OS (P = 0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy. CONCLUSIONS: Pretreatment tissue sampling in mTNBC treated with CNP reveals transcriptomic signatures that may predict radiographic responses to chemo-immunotherapy.
35
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text
Medicine, Oncology, Pharmacology +16
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat, Joel S. Parker, Olga Karginova et al. · Breast Cancer Research · 2010 · 2.1K citations · Full text
Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +16